ReviewExperimental and therapeutic medicine2022
Metabolic comorbidities of psoriasis (Review).
Review in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Gene therapy for uveal melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- A Triple-Hit Multi-Omics Framework for Psoriasis: Microbial Metabolic Remodeling and Immune Cell Methylome Signature Associated with an AMP-Dominant Lesional Program.Life (Basel, Switzerland) · 2026Article
- Nanoformulations in Acne Therapy: Translational Opportunities and Barriers for Next-Generation Topical Treatments.AAPS PharmSciTech · 2026Review
- Advances in Psoriasis Research: Decoding Immune Circuits and Developing Novel Therapies.International journal of molecular sciences · 2025Review
- Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- Effects of the ketogenic diet on skin-potential benefits and risks.Frontiers in nutrition · 2025Review
- Skin Care Supports Overall Well-Being.Clinical, cosmetic and investigational dermatology · 2025Article
- The Role of Metabolic Syndrome in Psoriasis Treatment Response: A One-Year Comparative Analysis of PASI Progression.Diagnostics (Basel, Switzerland) · 2024Article
- Psoriasis: The Versatility of Mesenchymal Stem Cell and Exosome Therapies.Biomolecules · 2024Review
- Novel Fatty Acid Biomarkers in Psoriasis and the Role of Modifiable Factors: Results from the METHAP Clinical Study.Biomolecules · 2024Article
- Clinical Implications of Metabolic Syndrome in Psoriasis Management.Diagnostics (Basel, Switzerland) · 2024Article
- Efficacy and Safety of Topical Tacrolimus Microemulsion Applied Twice Daily in Patients with Mild to Moderate Scalp Psoriasis.Dermatology and therapy · 2024Article
- Patient perspective on psoriasis: Psychosocial burden of psoriasis and its management in Malaysia.PloS one · 2024Article
- Article
- The Association of Telangiectasias with Other Peripheral Vascular Lesions of Systemic Sclerosis.Clinical, cosmetic and investigational dermatology · 2024Article
- Investigating Chronotype and Sleep Quality in Psoriatic Patients: Results from an Observational, Web-Based Survey.Journal of personalized medicine · 2023Article
- Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: a prospective study.Medicine and pharmacy reports · 2023Article
- Chinese Medicine as Supporting Therapy for Psoriasis: Past, Present, and Future.Chinese journal of integrative medicine · 2023Review
- Knowledge Mapping and Research Hotspots of Comorbidities in Psoriasis: A Bibliometric Analysis from 2004 to 2022.Medicina (Kaunas, Lithuania) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory and immune-mediated condition, which is no longer considered as being limited to the skin, but may affect the entire body. Epidemiological studies have shown that certain disorders, including obesity, diabetes, liver abnormalities, elevated lipid levels in the blood and metabolic syndrome, may occur more frequently in patients with psoriasis compared with the general population. As psoriasis is a chronic disease, the frequently associated comorbidities must be identified early to ensure timely treatment and, possibly, their prevention. Comorbidities often manifest clinically 1-2 years after the onset of psoriasis and are commonly seen in patients with severe forms of the disease. The association between psoriasis and its comorbidities is not coincidental, but rather based on common pathophysiological mechanisms and risk factors that underlie the increased frequency of comorbidities in patients with psoriasis. The aim of the present review was to emphasize the important role of dermatologists in the early recognition of comorbidities in patients with psoriasis, with a focus on metabolic comorbidities, precisely because the dermatologists are usually the first medical contact due to the predominance of skin lesions. Therefore, these specialists have the responsibility to inform patients on the association between psoriasis and possible multiple comorbidities, devise prevention and treatment plans, or even redirect patients to other specialists.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.